Skip to main
TXG

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 15%
Buy 15%
Hold 62%
Sell 0%
Strong Sell 8%

Bulls say

10x Genomics Inc. has demonstrated a robust market position with increasing Chromium reaction volumes, indicating strong demand for its integrated solutions amid challenges in the pharmaceutical sector. The projected growth of consumables by 5 to 19 times per platform by 2027 highlights the potential for significant revenue expansion, as these consumables are expected to outpace instrument revenue growth. Furthermore, the company's comprehensive product offerings in the life sciences technology market position it favorably to capitalize on ongoing and future investments in biological analysis.

Bears say

10x Genomics has experienced a contraction in 2024, marked by double-digit pricing pressure and flat to modestly lower volumes, with growth anticipated to stagnate until 2027. The company reported weaker than expected Q4 results, missing earnings per share estimates significantly and projecting a full-year revenue outlook that fell short of expectations. Additionally, despite some expansion in business segments since the company's peak stock prices in 2021, the overall performance has not met analyst expectations, contributing to a decline of over 90% in stock value since that peak.

10X Genomics (TXG) has been analyzed by 13 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 15% recommend Buy, 62% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Hold based on their latest research and market trends.

According to 13 analysts, 10X Genomics (TXG) has a Hold consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.